PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.
| dc.contributor.author | Gupta, A | |
| dc.contributor.author | Anjomani-Virmouni, S | |
| dc.contributor.author | Koundouros, N | |
| dc.contributor.author | Poulogiannis, G | |
| dc.date.accessioned | 2018-01-24T15:39:46Z | |
| dc.date.issued | 2017-01-01 | |
| dc.identifier.citation | Molecular & cellular oncology, 2017, 4 (6), pp. e1329692 - ? | |
| dc.identifier.issn | 2372-3556 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1025 | |
| dc.identifier.eissn | 2372-3556 | |
| dc.identifier.doi | 10.1080/23723556.2017.1329692 | |
| dc.description.abstract | Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)-which is genetically linked to PD-promotes cancer progression via redox-mediated inactivation of phosphatase and tensin homolog (PTEN) by S-nitrosylation. | |
| dc.format | Electronic-eCollection | |
| dc.format.extent | e1329692 - ? | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | TAYLOR & FRANCIS INC | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
| dc.title | PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2017-05-09 | |
| rioxxterms.versionofrecord | 10.1080/23723556.2017.1329692 | |
| rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
| rioxxterms.licenseref.startdate | 2017-01 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Molecular & cellular oncology | |
| pubs.issue | 6 | |
| pubs.notes | No embargo | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism | |
| pubs.publication-status | Published | |
| pubs.volume | 4 | |
| pubs.embargo.terms | No embargo | |
| icr.researchteam | Signalling & Cancer Metabolism | |
| dc.contributor.icrauthor | Koundouros, Nikolaos | |
| dc.contributor.icrauthor | Poulogiannis, Georgios |
Files in this item
This item appears in the following collection(s)
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0